University of Miami gifts 1994 ibogaine IND to HHS

The University of Miami has donated its 1994 Investigational New Drug (IND) application for ibogaine to the U.S. Department of Health and Human Services (HHS), according to the Multidisciplinary Association for Psychedelic Studies (MAPS). This move is seen as a significant step towards promoting open science in the field of psychedelic research.

Background on the 1994 IND

The 1994 IND, initially supported by MAPS, was a pioneering effort to study ibogaine, a psychoactive compound with potential therapeutic applications for opioid use disorder and other conditions. An IND is a critical regulatory document that allows researchers to conduct clinical trials with investigational drugs under the supervision of the U.S. Food and Drug Administration (FDA). The University of Miami's decision to make this document publicly available is notable, as it reflects the state of knowledge about ibogaine at the time, including its pharmacology, dosing, and associated risks.

Advancements in Ibogaine Research

Since the original filing, significant progress has been made in understanding ibogaine's effects, particularly its cardiac risks and pharmacokinetics. MAPS has published an updated Ibogaine Investigator’s Brochure, consolidating three decades of research data. This resource is freely available to academics, clinicians, and policymakers, aiming to facilitate informed and responsible use of ibogaine in clinical settings.

Why it matters

The donation of the 1994 IND to HHS underscores a commitment to transparency and collaboration in psychedelic research. By making this information accessible, the University of Miami and MAPS hope to inspire other researchers to prioritize open science and ethical practices. This approach is crucial as the field continues to evolve, ensuring that new studies build on a comprehensive understanding of ibogaine's benefits and risks.

Ethical and Environmental Considerations

MAPS emphasizes the importance of ethical considerations in ibogaine research, particularly regarding the plant's origins in Gabon. The organization advocates for sustainable practices that respect the communities and ecosystems where iboga is sourced. As interest in ibogaine grows, MAPS calls for rigorous screening and monitoring protocols to ensure participant safety in clinical trials.

The University of Miami's contribution of the 1994 ibogaine IND to the public domain is a significant gesture towards fostering open science and collaboration in psychedelic research. This move could set a precedent for other institutions to follow, promoting a more transparent and ethical approach to developing psychedelic therapies.